


Searching News Database: CRISPR
HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
HSMN NewsFeed - 7 Mar 2023
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 13 Sep 2021
ViaCyte Appoints Stem Cell Therapy Expert Dr. Timothy Kieffer as Chief Scientific Officer
ViaCyte Appoints Stem Cell Therapy Expert Dr. Timothy Kieffer as Chief Scientific Officer
HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
HSMN NewsFeed - 8 Jan 2021
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
HSMN NewsFeed - 7 May 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
HSMN NewsFeed - 8 Aug 2019
Bayer Acquires Bluerock Therapeutics to Build Leading Position in Cell Therapy
Bayer Acquires Bluerock Therapeutics to Build Leading Position in Cell Therapy
HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
HSMN NewsFeed - 29 Nov 2018
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
HSMN NewsFeed - 20 Feb 2017
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
HSMN NewsFeed - 8 Dec 2016
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer
